PCSK9 and familial hypercholesterolemia: The use of PCSK9 inhibitors represents a new approach to lower cholesterol in patients with hypercholesterolemia, achieving significant reductions in circulating cholesterol by stabilizing LDLr in the hepatocyte membrane and increasing cholesterol uptake (Sabatine, 2019).